Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug to treat erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are main desired properties. Dicot's main strategy is to develop LIB-01 in-house up to and including clinical phase 2a study, and then in partnership with major pharmaceutical companies to finance and further develop LIB-01 into a registered drug for the world market.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Avanza Pension | 10,45 | 10,45 | 2024-09-26 |
| Bertil Lindkvist | 8,26 | 8,26 | 2024-06-26 |
| Nordnet Pensionsförsäkring | 3,62 | 3,62 | 2024-09-26 |
| Tore Robertsson | 3,20 | 3,20 | 2024-09-26 |
| Torsten Söderberg med familj | 1,91 | 1,91 | 2024-09-26 |
| Stefan Henriksson | 1,30 | 1,30 | 2024-09-26 |
| Klas Göran Viktor Strömberg | 1,03 | 1,03 | 2024-09-26 |
| Michael Zell | 0,92 | 0,92 | 2024-09-26 |
| Wilhelm Risberg | 0,85 | 0,85 | 2024-09-26 |
| Fredrik Lundgren | 0,83 | 0,83 | 2024-09-26 |
2024-10-31 Delårsrapport 2024-Q3
2025-02-13 Bokslutskommuniké 2024
